News vs Noise

Randomised controlled trial in 66 adults aged 65–90. Statistically significant improvement in muscle endurance and mitochondrial gene expression vs placebo. Largest urolithin A RCT to date.

TAME is the first FDA-approved clinical trial treating aging itself as an indication. Completion of enrolment is a landmark step. Results expected 2027–2028. Rigorously designed multi-centre RCT.

Interim results from the PEARL trial show favourable changes in epigenetic clock biomarkers at 5 mg weekly intermittent dosing. Adverse event profile was acceptable. Larger confirmatory trial now planned.

Well-designed crossover pharmacokinetics study in 30 healthy adults. Pterostilbene achieves 4x higher plasma AUC and 2x longer half-life than resveratrol at equivalent doses. Clear, reproducible result with clinical implications for supplementation choice.

12-week RCT in 99 adults over 65. Urolithin A (1000 mg/day) improved VO2max, muscle endurance, and mitochondrial health markers versus placebo. Pre-specified endpoints met. Sponsor-independent analysis conducted.

Multi-centre RCT in 180 patients. Berberine 1500 mg/day achieved equivalent HbA1c reduction to metformin 1500 mg/day at 3 months, with better GI tolerability profile. Adds to growing body of clinical berberine evidence.

10-year follow-up of the Q-SYMBIO RCT (n=420). CoQ10 300 mg/day in heart failure patients achieved 40% reduction in all-cause mortality vs placebo. One of the strongest supplement RCTs for mortality as a primary endpoint.

Meta-analysis of 17 RCTs (n=77,000+). High-dose EPA-enriched omega-3 (prescription-grade, 4g/day) significantly reduces major adverse cardiovascular events in patients with elevated triglycerides. Distinction from low-dose fish oil supplements is important.

12-week RCT in 109 adults aged 50–70. Magnesium L-threonate significantly outperformed placebo on cognitive composite scores and showed increased synaptic density in imaging sub-study. Funded by a third party with no commercial interest.

Comprehensive narrative review of 200+ studies. Creatine evidence base for muscle and strength is among the strongest in sports nutrition. Emerging evidence for cognitive support and bone health in older adults. Low cost, excellent safety profile.

Long-term follow-up data from the VITAL trial (n=25,871). While Vitamin D did not prevent cancer incidence, it significantly reduced cancer mortality in those who developed cancer. High-quality RCT design with pre-specified outcomes.

Pharmacokinetics study confirms free curcumin is virtually undetectable in blood after standard capsule doses. Only liposomal, phytosome, or piperine-enhanced formulations achieve meaningful plasma levels. Important warning for consumers buying standard curcumin.

Well-conducted 8-week RCT in 64 chronically stressed adults. KSM-66 extract (600mg/day) achieved 27% cortisol reduction and significant improvements on PSQI sleep scale vs placebo. Consistent with prior RCT data.

RCT in 72 older adults. GlyNAC supplementation significantly restored glutathione levels, improved insulin sensitivity, reduced oxidative stress markers, and improved grip strength vs placebo. Well-designed trial from Baylor College of Medicine.

RCT in 120 patients with statin-associated myopathy. CoQ10 200mg/day significantly reduced pain, weakness, and creatine kinase levels vs placebo over 12 weeks. Supports clinical practice of CoQ10 co-supplementation with statins.

3-year RCT in 244 post-menopausal women. K2 MK-7 (180 mcg/day) significantly slowed coronary artery calcium score progression vs placebo. Strong mechanistic rationale (matrix Gla protein activation). Pre-registered, industry-independent funding.

Prospective observational study (n=4,200, 10-year follow-up). CGM-derived time-in-range and glycaemic variability metrics significantly predicted MACE independently of HbA1c. Supports value of CGM beyond diabetes management.